Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480241 | 1.00 | GRM2 (0.43) | GRM2MMP1MMP13MAPTGAA | |
| SCHEMBL12480539 | 1.00 | GRM2 (0.43) | GRM2MMP1MMP13MAPTGAA | |
| SCHEMBL2800737 | 0.82 | SMN1; SMN2 (0.48) | GRM2MMP1MMP13GAAKMT2A | |
| SCHEMBL27810603 | 0.79 | GRM2 (0.42) | GRM2MMP1MMP13MAPTGAA | |
| SCHEMBL12480983 | 0.75 | GAA (0.49) | MAPTGAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL12481865 | 0.74 | GAA (0.42) | GRM2MAPTGAAKDM4EKMT2A | |
| SCHEMBL15333789 | 0.73 | GAA (0.41) | MAPTGAAKDM4EKMT2AALDH1A1 | |
| SCHEMBL3799855 | 0.73 | NPSR1 (0.44) | GRM2MMP1MMP13MAPTGAA | |
| SCHEMBL15333639 | 0.72 | ALK (0.51) | MAPT | |
| SCHEMBL31715206 | 0.68 | AURKA (0.52) | GRM2GAAKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661437-B1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2018-11-07 | — | — | EP | disclosed |
| US-9428508-B2 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9428508-B2 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9428508-B2 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| EP-2661437-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | Centaurus Biopharma Co., Ltd. (CN) | 2013-11-13 | — | — | EP | disclosed |
| US-20130281438-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
| US-20130281438-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
| US-20130281438-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
| WO-2012092880-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281438-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | PTK2B, PTK2, DAPK2 | GRM2 1095/4885MMP1 3576/4885MMP13 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.